1. Longitudinal support for the correlative triad among aging, dopamine D2-like receptor loss, and memory decline
- Author
-
Karalija, Nina, Papenberg, Goran, Johansson, Jarkko, Wåhlin, Anders, Salami, Alireza, Andersson, Micael, Axelsson, Jan, Kuznetsov, Dmitry, Riklund, Katrine, Lövdén, Martin, Lindenberger, Ulman, Bäckman, Lars, Nyberg, Lars, Karalija, Nina, Papenberg, Goran, Johansson, Jarkko, Wåhlin, Anders, Salami, Alireza, Andersson, Micael, Axelsson, Jan, Kuznetsov, Dmitry, Riklund, Katrine, Lövdén, Martin, Lindenberger, Ulman, Bäckman, Lars, and Nyberg, Lars
- Abstract
Dopamine decline is suggested to underlie aging-related cognitive decline, but longitudinal examinations of this link are currently missing. We analyzed 5-year longitudinal data for a sample of healthy, older adults (baseline: n = 181, age: 64–68 years; 5-year follow-up: n = 129) who underwent positron emission tomography with 11C-raclopride to assess dopamine D2-like receptor (DRD2) availability, magnetic resonance imaging to evaluate structural brain measures, and cognitive tests. Health, lifestyle, and genetic data were also collected. A data-driven approach (k-means cluster analysis) identified groups that differed maximally in DRD2 decline rates in age-sensitive brain regions. One group (n = 47) had DRD2 decline exclusively in the caudate and no cognitive decline. A second group (n = 72) had more wide-ranged DRD2 decline in putamen and nucleus accumbens and also in extrastriatal regions. The latter group showed significant 5-year working memory decline that correlated with putamen DRD2 decline, along with higher dementia and cardiovascular risk and a faster biological pace of aging. Taken together, for individuals with more extensive DRD2 decline, dopamine decline is associated with memory decline in aging.
- Published
- 2024
- Full Text
- View/download PDF